SCHEMBL4399686

SCHEMBL4399686

CCO[P@@](C)(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93840 1.00
SCHEMBL17737221 1.00
SCHEMBL28054070 0.97
SCHEMBL28054038 0.97
SCHEMBL17626439 0.97
SCHEMBL17626450 0.97
SCHEMBL17626498 0.97
SCHEMBL28276955 0.89 TSHR (0.46)
Acetaldehyde SCHEMBL28215663 0.89 TSHR (0.43)
SCHEMBL27998823 0.89 TSHR (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982245-B1 CYANINE DYES FOR LABELING OF TARGET MOLECULES, IDENTIFICATION OF ORGANELLES AND OTHER APPLICATIONS ENZO LIFE SCIENCES INC (US) 2018-08-08 EP disclosed
US-9834710-B2 Adhesive compositions and methods SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2017-12-05 US disclosed
US-20170260219-A1 PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-09-14 US disclosed
US-9663543-B2 Phosphonate compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9650341-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2017-05-16 US disclosed
US-9638690-B2 Compounds and compositions for use as alkylating agent sensors and methods of use thereof THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-05-02 US disclosed
US-9598726-B2 Method for enhancing efficiency and sensitivity in nucleic acid amplification from biological materials using ionic liquids SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-03-21 US disclosed
US-20170073653-A1 POLYPEPTIDES HAVING ORGANOPHOSPHOROUS HYDROLASE ACTIVITY NOVOZYMES A/S (DK) 2017-03-16 US disclosed
US-20170022319-A1 ALIPHATIC POLYCARBONATE POLYOL COMPOSITIONS SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2017-01-26 US disclosed
US-20160362432-A1 PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2016-12-15 US disclosed
US-20090247966-A1 METHODS AND PRODUCTS FOR APPLYING STRUCTURED COMPOSITIONS TO A SUBSTRATE JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2009-10-01 US disclosed
EP-2005453-B1 ELECTRET MATERIALS BASF SE (DE) 2009-09-09 EP disclosed
US-7534809-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2009-05-19 US disclosed
US-20090005462-A1 STRUCTURED DEPILATORY COMPOSITIONS APPLIED OPTOELECTRONICS INC 2009-01-01 US disclosed
US-20080227104-A1 Replication; hybridization; kits RIKEN (JP) 2008-09-18 US disclosed
US-20080125383-A1 For host undergoing surgery or coronary artery bypass TOBIRA THERAPEUTICS, INC. 2008-05-29 US disclosed
US-20080112913-A1 LOW-IRRITATION COMPOSITIONS AND METHODS OF MAKING THE SAME KENVUE BRANDS LLC 2008-05-15 US disclosed
WO-2007096362-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASE TRIGEN LIMITED (GB) 2007-08-30 WO disclosed
US-20070111910-A1 Low-irritation compositions and methods of making the same JOHNSON & JOHNSON CONSUMER INC. 2007-05-17 US disclosed
US-7186737-B2 Inhibitors of p38 VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-03-06 US disclosed